As the top selling five biological products face patent expiration in the US, more companies are poised to move into biosimilars. With the regulatory pathway now established, there is no doubt that the competition to commercialise will be tight. Which strategies have proven the most effective for the EU market? And what impact might they have in the US market? Learn more.
Teva said Wednesday that 15 new therapeutic entities (NTEs) have entered its development pipeline since the launch of the programme last year, with the compounds forecast by the company to generate $3... Read More >>